Cosopt®
Dorzolamide 2% / Timolol 0.5% · ophthalmic solution
Antiglaucoma
Approved uses
Elevated IOP in open-angle glaucoma or ocular hypertension inadequately controlled on a beta-blocker
1 drop in the affected eye(s) BID
Lowers IOP a further 14 to 20% over timolol alone, matching its components given separately.
OFF-LABELNot in the FDA label for this product
IOP spike prophylaxis before intravitreal anti-VEGF injection
1 drop 1 hour before the injection; a 2-drop regimen of 1 drop at 1 hour and 1 drop at 5 minutes before was also studied
Trial · n=89 · not indexed RCT
Randomized, double-masked trial, 308 patients contributing one eye each, of which 89 received this product by brand name: mean IOP at 30 minutes post-injection stayed within 21 mmHg and was back to baseline at 1 hour, while the untreated group rose 7.84 mmHg at 30 minutes and remained 4.05 mmHg above baseline at 1 hour. Premedication blunted rather than abolished the spike (still up 2.31 mmHg with one drop and 1.71 mmHg with two at 30 minutes), the 32 controls were not randomized but were patients excluded from the drug arms for allergy or contraindication, and the three fixed combinations tested performed comparably.
Contraindications
- Bronchial asthma or a history of bronchial asthma.
- Severe chronic obstructive pulmonary disease.
- Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock.
- Hypersensitivity to any component of this product.
Dorzolamide 2% (20 mg/mL) and timolol 0.5% (5 mg/mL) ophthalmic solution, benzalkonium chloride preserved, 10 mL bottle
Fixed combination of dorzolamide, a human carbonic anhydrase II inhibitor, and timolol, a nonselective beta-1 and beta-2 adrenergic blocker without significant intrinsic sympathomimetic, direct myocardial depressant, or membrane-stabilizing activity; each component reduces aqueous humor secretion. Given BID the pair lowers IOP more than either component alone, but not as much as dorzolamide TID plus timolol BID administered concomitantly.
Warnings & Precautions
- Potentiation of respiratory reactions including asthma: Timolol is absorbed systemically from topical dosing, so the same types of adverse reactions attributable to systemic beta-blockers may occur. Severe respiratory reactions including death due to bronchospasm in patients with asthma, and rarely death associated with cardiac failure, have been reported after systemic or ophthalmic timolol.
- Cardiac failure: Sympathetic stimulation may be essential to support the circulation in individuals with diminished myocardial contractility, and beta-blockade may precipitate more severe failure. In patients without a history of cardiac failure, continued myocardial depression over time can, in some cases, lead to cardiac failure. Discontinue at the first sign or symptom of cardiac failure.
- Sulfonamide hypersensitivity: Dorzolamide is a sulfonamide that is absorbed systemically despite topical dosing, so the reactions attributable to sulfonamides may occur, rarely fatal, including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Sensitization may recur when a sulfonamide is readministered by any route; discontinue if a serious reaction or hypersensitivity occurs.
- Obstructive pulmonary disease: Patients with mild or moderate COPD, bronchospastic disease, or a history of bronchospastic disease should in general not receive beta-blockers; asthma, a history of asthma, and severe COPD are contraindications.
- Increased reactivity to allergens: Patients with a history of atopy or of severe anaphylaxis may be more reactive to allergen challenge while on a beta-blocker and may be unresponsive to the usual doses of epinephrine.
- Potentiation of muscle weakness: Beta-blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness. Timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms.
- Masking of hypoglycemic symptoms: Beta-blockers may mask the signs and symptoms of acute hypoglycemia; caution in spontaneous hypoglycemia and in diabetic patients (especially those with labile diabetes) on insulin or oral hypoglycemics.
- Masking of thyrotoxicosis: Beta-blockers may mask tachycardia and other signs of hyperthyroidism, and abrupt withdrawal may precipitate thyroid storm.
- Renal and hepatic impairment: Not recommended at CrCl below 30 mL/min, since dorzolamide and its metabolite are excreted predominantly by the kidney; not studied in hepatic impairment, so use with caution there.
- Impaired beta-adrenergic reflexes during surgery: Blockade impairs the heart's response to reflex adrenergic stimuli; protracted severe hypotension during anesthesia and difficulty restarting and maintaining the heartbeat have been reported.
- Corneal endothelium: Carbonic anhydrase activity is present in the corneal endothelium, and patients with low endothelial cell counts have an increased potential for corneal edema. Use caution when prescribing COSOPT to these patients.
- Bacterial keratitis: Reported with inadvertently contaminated multi-dose containers, in most cases in patients with a concurrent corneal disease or a disruption of the ocular epithelium.
- Absorption of benzalkonium chloride by soft contact lenses: COSOPT contains benzalkonium chloride, which may be absorbed by soft contact lenses; remove lenses before instillation and reinsert 15 minutes after.
- Additive systemic effects of carbonic anhydrase inhibition: There is a potential for an additive effect with an oral carbonic anhydrase inhibitor, and concomitant use of COSOPT and oral carbonic anhydrase inhibitors is not recommended.
- Acid-base and electrolyte disturbances: Not reported in the dorzolamide trials, but reported with oral carbonic anhydrase inhibitors, where they have in some instances resulted in drug interactions such as toxicity with high-dose salicylate therapy; consider the potential for such interactions in patients receiving COSOPT.
- Potentiated systemic beta-blockade: Observe patients on an oral beta-blocker for potential additive effects of beta-blockade, systemic and on IOP; two topical beta-blockers are not recommended. Potentiated systemic beta-blockade has been reported with CYP2D6 inhibitors (e.g., quinidine, SSRIs). Catecholamine-depleting drugs such as reserpine may have additive effects and produce hypotension and/or marked bradycardia, so close observation is recommended.
- Atrioventricular conduction disturbances: Use caution with oral or IV calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, and hypotension; in patients with impaired cardiac function, coadministration should be avoided. Digitalis with calcium antagonists may have additive effects in prolonging atrioventricular conduction time.
Common Side Effects
The most frequent adverse reactions, in up to 30% of patients, were taste perversion (bitter, sour, or unusual taste) and ocular burning and/or stinging. Conjunctival hyperemia, blurred vision, superficial punctate keratitis, and eye itching were reported in 5 to 15% of patients. Reactions reported in 1 to 5% of patients included blepharitis, conjunctivitis, conjunctival edema, corneal erosion, corneal staining, dryness of eyes, eye pain, eyelid edema, foreign body sensation, lens opacity, headache, dizziness, cough, bronchitis, sinusitis, upper respiratory infection, hypertension, nausea, and back pain. Approximately 5% of patients discontinued therapy because of adverse reactions. Reactions reported with the individual components include arrhythmia, syncope, and cardiac arrest with timolol, and angioedema, transient myopia, and contact dermatitis with dorzolamide.
Pregnancy: No adequate and well-controlled studies in pregnant women; use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Oral dorzolamide in rabbits at 2.5 mg/kg/day and above (37 times the recommended human ophthalmic dose) caused vertebral body malformations at doses that also caused maternal metabolic acidosis and decreased fetal weights, with no treatment-related malformations at 1 mg/kg/day (15 times); timolol showed no fetal malformations in mice, rats, or rabbits at oral doses up to 50 mg/kg/day.
Lactation: Timolol is detected in human milk after oral and ophthalmic dosing, and whether dorzolamide is excreted in human milk is unknown; decide between discontinuing nursing and discontinuing the drug.
Safety and effectiveness of the individual components are established at 2 years and older; not established below 2 years.